Estimates for the frequency of PTEN mutations in prostate cancer vary widely, between around 15% and 60%, depending on the type and stage of the disease, but testing for the biomarker isn't ...

For example, around 15- 20% of patients with prostate cancer lack the tumour suppressor gene PTEN, which result in disease that is difficult to treat. PTEN serves largely as a biomarker of ...

Previous research has shown that this pathway, called the PI3K-AKT pathway, is frequently mutated in prostate cancer. Although the most common mutation, in a gene called Pten, had already been ...

We have used the SV-40 based TRAMP model of prostate cancer to explore the role of FGF2 and the PTEN tumor suppressor gene in prostate cancer progression. To accomplish this we crossed TRAMP mice to ...

The CAPItello-281 study evaluated the combination of Truqap, J&J’s JNJ Zytiga (abiraterone) and androgen deprivation therapy (ADT) in patients with PTEN-deficient de novo metastatic hormone ...

For example, advanced prostate cancer (PCa) is often linked to changes in the activity of a tumor suppressor, called phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and a widely ...

UK-based pharmaceutical company AstraZeneca has reported positive results from its Phase III CAPItello-281 trial, which evaluated Truqap combined with abiraterone and androgen deprivation therapy ...

Subsequent studies from other groups found that antioxidant response genes acted as oncogenes rather than tumor suppressors, prompting Trotman to explore an intriguing alternative: Could pro-oxidants ...

For example, advanced prostate cancer (PCa) is often linked to changes in the activity of a tumor suppressor, called phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and a widely ...

Table 2. Associations of brown fat, obesity and loss/mutation of tumor suppressor genes in endometrial and breast cancer. † P53 mutation in case of PTEN or BRCA1 mutation. ‡ Brown fat state in ...